安非他酮与喹硫平治疗双相情感障碍抑郁发作的临床疗效及安全性分析

目的 研究安非他酮与喹硫平治疗双相情感障碍抑郁发作的临床疗效及安全性。方法 选取2016年1月~2017年8月在我院治疗的双相情感障碍抑郁发作患者84例，随机分为安非他酮组和喹硫平组，每组42例。安非他酮组采取口服安非他酮治疗，喹硫平组采取口服喹硫平治疗，治疗2个月后观察对比两组患者临床治疗有效率、生活质量评分、抑郁症状改善时间、抑郁评分、不良反应发生情况。结果 喹硫平组治疗总有效率、生活质量评分高于安非他酮组，差异有统计学意义（P＜0.05）；喹硫平组抑郁评分、不良反应发生率低于安非他酮组，且抑郁评分降低时间短于安非他酮组，差异有统计学意义（P＜0.05）。结论 喹硫平治疗双相情感障碍抑郁发作的临床疗效理想，可显著改善患者临床症状，且不良反应少，用药安全性高，值得临床推广。

Clinical Efficacy and Safety of Bupropion and Quetiapine in the Treatment of Bipolar Affective Disorder Depression

Abstract:Objective To study the efficacy and safety of bupropion and quinalapine in the treatment of bipolar affective disorder depression.Methods From January 2016 to August 2017,84 patients with bipolar depression were randomly divided into two groups: acetophenone group(n=42)and quetiapine group(n=42).The bupropion group was treated with oral bupropion and the quetiapine group was treated with oral quetiapine.After 2 months of treatment,clinical efficacy,quality of life scores,time to improvement of depressive symptoms,and depression scores were observed and compared between the two groups,the occurrence of adverse reactions.Results Quetiapine treatment group total effective rate, quality of life score higher than the bupropion group,the difference was statistically significant(P<0.05);occurrence of quetiapine group depression score,adverse reaction rate is lower than the bupropion group and depression scores decreased time shorter than the bupropion group,the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of quetiapine in the treatment of depressive episodes of bipolar disorder is satisfactory.It can significantly improve the clinical symptoms of patients,and has fewer adverse reactions.The safety of medication is high and worthy of clinical promotion.